91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

首页
应用
蛋白质生物学
流式细胞术
Infliximab (anti-TNF-alpha)

Infliximab (anti-TNF-alpha)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Cynomolgus,Human
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
I412009-1mg	1mg	现货
I412009-5mg	5mg	现货
I412009-10mg	10mg	期货

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Infliximab (anti-TNF-alpha)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	TNFSF2/TNFa
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属	Cynomolgus,Human
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	27.6 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 186.7 kDa, under non-reducing conditions.
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	170277-31-3

数据库链接

Wikipedia	Infliximab
IMGT/mAb-DB	156
PubChem SID	178101701
PEP	infliximab
Immunopaedia Search	infliximab

关联配体

Ligand ID

5004

名称

infliximab

别名

Remicade®

类别

Antibody

学名

4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide

生物活性评价

Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohn's disease patients (47 tested) . This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments).

评价

Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 .

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications
infliximab-dyyb; CT-P13	Remsima; Inflectra; Flammegis	Celltrion/Pfizer	Approved (2013 EMA, 2016 FDA)	As per reference agent
infliximab-abda; SB2	Flixabi; Renflexis	Merck/SamsungBioepis	Approved (2016 EMA, 2017 FDA)	As per reference agent
infliximab-qbtx; PF-06438179	Ixifi; Zessly	Pfizer?Sandoz	Approved (2017 FDA, 2018 EMA)	As per reference agent
NI-071		Nichi-Iko Pharmaceutical	Approved (2017 Japan); Phase 3 US (NCT02990806)	As per reference agent
BCD-055		Biocad	Ph 3 (NCT02762838)	Rheumatoid arthritis
Infliximab-EPIRUS; BOW015	Infimab	Epirus Biopharmaceuticals	Approved (2014 India); Ph 3 US (NCT02683564)	Rheumatoid arthritis
infliximab-axxq; ABP710	Avsola	Amgen	Approved (2019 FDA)	As per reference agent
STI-002		MabTech/Sorrento Therapeutic
Infliximab biosimilar 1		Nippon Kayaku	Approved (Japan 2014)	As per reference agent

Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent .

单字母多肽序列

三字母多肽序列

翻译后修饰

化学修饰

参考文献

1. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.. Gastroenterology, 117 (4): (761-9). [PMID:10500056]
2. Blair HA, Deeks ED. (2016) Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.. BioDrugs, 30 (5): (469-480). [PMID:27650650]
3. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.. Ann Rheum Dis, 76 (2): (355-363). [PMID:27130908]
4. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016) Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(?) (Infliximab).. Adv Ther, 33 (11): (1964-1982). [PMID:27585978]
5. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).. Gastroenterology, 109 (1): (129-35). [PMID:7797011]
6. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033]

图片

ELISA: Infliximab (anti-TNF-alpha) (I412009)

Infliximab (anti-TNF-alpha) (I412009) - ELISA
Immobilized Recombinant Human TNF-alpha Protein (rp156007) at 0.5 μg/mL can bind Infliximab (anti-TNF-alpha) (I412009) with the EC?? of 31.52 ng/mL.

SEC: Infliximab (anti-TNF-alpha) (I412009)

Infliximab (anti-TNF-alpha) (I412009) - SEC
The purity of Infliximab (anti-TNF-alpha) (I412009) is more than 95% verified by HPLC.

产品问答

登录提交问题

查看全部

您好，Infliximab (anti-TNF-alpha)，货号I412009-1mg，网站页说到，储存缓冲液为Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0。请问100mM Pro-AC是什么物质，Pro-AC是protein A和protein C吗？

问题由韦晓云于 2023年10月26日 11:09 创建

您好，该产品的储存缓冲液Pro-AC是指脯氨酸醋酸缓冲液。